Spellicy C J, Harding M J, Hamon S C, Mahoney J J, Reyes J A, Kosten T R, Newton T F, De La Garza R, Nielsen D A
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine and Michael E. DeBakey V.A. Medical Center, Houston, TX.
Genes Brain Behav. 2014 Jul;13(6):559-64. doi: 10.1111/gbb.12121. Epub 2014 Mar 17.
This study aimed to evaluate whether functional variants in the ankyrin repeat and kinase domain-containing 1 (ANKK1) gene and/or the dopamine receptor D2 (DRD2) gene modulate the subjective effects (reward or non-reward response to a stimulus) produced by cocaine administration. Cocaine-dependent participants (N = 47) were administered 40 mg of cocaine or placebo at time 0, and a subjective effects questionnaire (visual analog scale) was administered 15 min prior to cocaine administration, and at 5, 10, 15 and 20 min following administration. The influence of polymorphisms in the ANKK1 and DRD2 genes on subjective experience of cocaine in the laboratory was tested. Participants with a T allele of ANKK1 rs1800497 experienced greater subjective 'high' (P = 0.00006), 'any drug effect' (P = 0.0003) and 'like' (P = 0.0004) relative to the CC genotype group. Although the variant in the DRD2 gene was shown to be associated with subjective effects, linkage disequilibrium analysis revealed that this association was driven by the ANKK1 rs1800497 variant. A participant's ANKK1 genotype may identify individuals who are likely to experience greater positive subjective effects following cocaine exposure, including greater 'high' and 'like', and these individuals may have increased vulnerability to continue using cocaine or they may be at greater risk to relapse during periods of abstinence. However, these results are preliminary and replication is necessary to confirm these findings.
本研究旨在评估锚蛋白重复序列和激酶结构域包含蛋白1(ANKK1)基因和/或多巴胺受体D2(DRD2)基因中的功能性变异是否会调节可卡因给药产生的主观效应(对刺激的奖赏或无奖赏反应)。对可卡因依赖的参与者(N = 47)在时间0给予40 mg可卡因或安慰剂,并在可卡因给药前15分钟以及给药后5、10、15和20分钟进行主观效应问卷调查(视觉模拟量表)。测试了ANKK1和DRD2基因多态性对实验室中可卡因主观体验的影响。与CC基因型组相比,携带ANKK1 rs1800497 T等位基因的参与者经历了更强的主观“兴奋感”(P = 0.00006)、“任何药物效应”(P = 0.0003)和“喜欢”(P = 0.0004)。尽管DRD2基因中的变异显示与主观效应相关,但连锁不平衡分析表明,这种关联是由ANKK1 rs1800497变异驱动的。参与者的ANKK1基因型可能识别出那些在接触可卡因后可能经历更强积极主观效应的个体,包括更强的“兴奋感”和“喜欢”,并且这些个体可能有更高的继续使用可卡因的易感性,或者在禁欲期间复发的风险可能更高。然而,这些结果是初步的,需要重复实验来证实这些发现。